Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001
November 10, 2015 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...
ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors
November 04, 2015 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...
Oryzon Announces Oral Presentation on ORY-2001 at 8th Annual Clinical Trials on Alzheimer's Disease Conference
November 02, 2015 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...